Symbiotec Pharmalab IPO

Symbiotec Pharmalab Ltd., incorporated in 2002, is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves both domestic and international markets across regulated as well as emerging regions.

The company focuses on research-driven manufacturing, quality compliance, and sustainable production practices. It caters to the pharmaceutical, nutraceutical, and wellness industries by supplying high-quality ingredients developed in line with global standards.

With more than 30 years of industry experience, Symbiotec has grown from a small-scale steroidal-hormone API manufacturer in 1995 into a large, backward-integrated manufacturing platform. The company has received approvals from regulatory authorities and organisations such as the US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea, among others.

Operations & Manufacturing 

As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.

Competitive Strengths

• Strong position in corticosteroid and steroidal-hormone API manufacturing 

• Long-standing relationships with domestic and international customers 

• Vertically integrated manufacturing platform with a focus on sustainability and regulatory compliance 

• Continuous investment in research and development capabilities 

• Ability to expand product offerings through scientific expertise and intellectual property-driven innovation